Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.62 |
| ▸ | PGK2 | P07205 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ACP3 | P15309 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044969 | 0.83 | PGK1 (0.60) | PGK1PGK2NPSR1CYP1A2POLB | |
| SCHEMBL4544109 | 0.80 | PGK1 (0.41) | PGK1PGK2CYP1A2 | |
| SCHEMBL4544108 | 0.79 | PGK1 (0.40) | PGK1PGK2 | |
| SCHEMBL4544106 | 0.79 | PGK1 (0.40) | PGK1PGK2 | |
| SCHEMBL17489025 | 0.78 | PGK1 (0.53) | PGK1PGK2NPSR1CYP1A2TSHR | |
| SCHEMBL6044952 | 0.78 | PGK1 (0.53) | PGK1PGK2KCNH2 | |
| SCHEMBL16277737 | 0.73 | PGK1 (0.67) | PGK1PGK2ACP3 | |
| SCHEMBL18363067 | 0.73 | ENPP2 (0.41) | PGK1PGK2LAP3POLBLMNA | |
| SCHEMBL232550 | 0.72 | LAP3 (0.51) | LAP3POLBLMNATSHR | |
| SCHEMBL17537480 | 0.70 | PGK1 (0.58) | PGK1PGK2NPSR1ACP3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778699-A4 | TARGETING CHELANTS AND CHELATES | DOW GLOBAL TECHNOLOGIES INC (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1778699-A2 | TARGETING CHELANTS AND CHELATES | Dow Gloval Technologies Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060210479-A1 | Targeting chelants and chelates | DOW GLOBAL TECHNOLOGIES INC. (US) | 2006-09-21 | — | — | US | disclosed |
| WO-2006020779-A2 | TARGETING CHELANTS AND CHELATES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210479-A1 | Targeting chelants and chelates | CLTC, CALCOCO2, TFRC | PGK1 2785/4885PGK2 2466/4885NPSR1 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.